A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer

• DOI: 10.1093/jjco/hyaa140
• Publication Date: 2020-07-23T11:26:12Z
• Authors: Yoshiko Nanki; Hiroyuki Nomura; Naomi Iwasa; Keiko Saotome; Ai Dozen; Tomoko Yoshihama; Takuro Hirano; Shiho Hashimoto; Tatsuyuki Chiyoda; Wataru Yamagami; Fumio Kataoka; Daisuke Aoki
• Keywords: Gastrointestinal perforation; Fallopian tube cancer; Clinical endpoint

Abstract Objective this prospective cohort study aimed to assess the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients relapsed ovarian, fallopian tube or primary peritoneal cancer. Methods study, 40 cancer selected receive were enrolled. Patients poor general condition excluded. Each patient was monitored prospectively for adverse events, administration status, disease status survival. Treatment continued until intolerable events progression. The endpoint safety. Results plus platinum-based performed 30 (median cycle; 16.5), while non-platinum 10 5.5). Among bevacizumab-related hypertension occurred 80% patients, proteinuria 83%, mucositis 25%, bleeding 20%, thromboembolic 5.0% fistula 2.5%. Gastrointestinal perforation other life-threatening lethal not observed. Response rate median progression-free survival 73% 19.3 months chemotherapy, 30% 3.9 respectively. There no correlation between response occurrence such as proteinuria. Conclusion tolerable effective ovarian cancer, Hypertension are frequently managed properly continuing treatment.